No attachments available.
Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients
Contact and place of performance
Alexis Hudak
USA
A Multiple-Award Indefinite Delivery, Indefinite Quantity (IDIQ) contract was awarded to each of the following organizations in support of the Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Program under this RFP no. 75N91021R00007. 75N91021D00019 - University of Pittsburgh (Pittsburgh, PA) - awarded 9/24/2021 75N91021D00020 - Mayo Clinic (Rochester, MN) - awarded 9/23/2021 75N91021D00021 - SRI International (Menlo Park, CA) - awarded 9/23/2021
The National Institutes of Health, National Cancer Institute, awarded multiple Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to support the Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients program. These awards, issued under solicitation number 75N91021R00007, facilitate research and development services focused on health and applied research. The work falls under NAICS 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN12 for Health R&D Services; Health Care Services; Applied Research.
Three organizations received contracts for performance within the United States. SRI International in Menlo Park, California, and the Mayo Clinic in Rochester, Minnesota, received awards on September 23, 2021, under contract numbers 75N91021D00021 and 75N91021D00020, respectively. The University of Pittsburgh in Pittsburgh, Pennsylvania, was granted contract number 75N91021D00019 on September 24, 2021. This award notice was published on September 28, 2021, with Alexis Hudak serving as the point of contact.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.